Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 280 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Choroid Clear all

Conditions: Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma
Interventions: EGFR806-specific chimeric antigen receptor (CAR) T cell; Biological
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Year to 26 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: lomustine, temozolomide, thalidomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: pyrazoloacridine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Combretastatin A4 Phosphate, Age-related Macular Degeneration, AMD, CNV, Choroidal Neovascularization
Interventions: Combretastatin A-4 Phosphate; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®); Genetic · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 107
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
Interventions: Cixutumumab, Laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 17 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Houston, Texas

Conditions: Choroidal Neovascularization, Age-Related Maculopathy
Interventions: dexamethasone, ranibizumab, sham; Drug · Biological · Other
Lead sponsor: Allergan; Industry
Eligibility: 50 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boynton Beach, Florida

Conditions: Choroidal Neovascularization, Age-Related Macular Degeneration
Interventions: Periocular injection of triamcinolone acetonide 40mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 2
States / cities: Baltimore, Maryland • Portland, Oregon

Conditions: Choroidal Neovascularization, Age-related Macular Degeneration
Interventions: hI-con1, ranibizumab, Sham injection; Biological · Other
Lead sponsor: Iconic Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 48
States / cities: Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 44 more

Conditions: Healthy
Interventions: Avenanthramide-enriched oats; Other
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Choroid Plexus Tumors
Interventions: Carboplatin, Cyclophosphamide, Etoposide, Vincristine, Radiation Therapy; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Uveal Neoplasms, Choroid Neoplasms, Iris Neoplasms
Interventions: Fine needle aspiration biopsy; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Childhood Choroid Plexus Tumor, Childhood Medulloblastoma, Childhood Pineoblastoma, Childhood Soft Tissue Sarcoma, Childhood Supratentorial Primitive Neuroectodermal Tumor, Neuroblastoma, Osteosarcoma, Retinoblastoma, Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: filgrastim; Biological
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 1 Year to 25 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Idiopathic Polypoidal Choroidal Vasculopathy
Interventions: Zimura, Eylea; Drug
Lead sponsor: Ophthotech Corporation; Industry
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: ‘Aiea, Hawaii

Conditions: Hydrocephalus
Interventions: Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC), Ventriculoperitoneal Shunt; Procedure · Device
Lead sponsor: University of Utah; Other
Eligibility: 1 Day to 104 Weeks
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more

Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions: temsirolimus, pharmacological study, cytokine levels; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Duarte, California

Conditions: Age-Related Macular Degeneration
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Macular Degeneration, Age-related Macular Degeneration
Interventions: Pazopanib eye drops and Allergen Refresh Plus eye drops; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 2
States / cities: Fargo, North Dakota • Austin, Texas

Conditions: Neovascularization, Choroidal, Macular Degeneration, Age-Related
Interventions: Faricimab, Ranibizumab, Sham Procedure; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 25
States / cities: Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more

Conditions: Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma
Interventions: HER2-specific chimeric antigen receptor (CAR) T cell; Biological
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Year to 26 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2039
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma, Sarcoma
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, leucovorin calcium, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 10 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 17
States / cities: Honolulu, Hawaii • Scarborough, Maine • Grand Rapids, Michigan + 11 more

Conditions: Choroid
Interventions: Oral glucose; Dietary Supplement
Lead sponsor: Southern College of Optometry; Other
Eligibility: 21 Years to 35 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Brain and Central Nervous System Tumors
Interventions: O6-benzylguanine, carmustine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 51
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 40 more

Conditions: Polypoidal Choroidal Vasculopathy
Interventions: fosbretabulin, Saline; Drug
Lead sponsor: Mateon Therapeutics; Industry
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Bioavailability of Avenanthramide-Enriched Oats in Healthy Older Adults

Treatment of Tumors of the Choroid Plexus Epithelium

Validation of a Molecular Prognostic Test for Eye Melanoma

Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer

ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors

Genetic Study of Age-Related Macular Degeneration

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor

Effects of Acute Sugar Intake on Choroidal Thickness

O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors

Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)